Pemshil 500mg Injection
| Product Name | Pemshil Injection |
|---|---|
| Strength | 500 mg |
| Active Ingredient | Pemetrexed |
| Drug Class | Antifolate Antineoplastic Agent |
| Dosage Form | Injection (Lyophilized powder for infusion) |
| Route of Administration | Intravenous (IV) infusion |
| Packaging | Single-use vial |
| Storage Condition | Store below 25°C and protect from light |
| Prescription Required | Yes |
| Usage | Non-small cell lung cancer, malignant pleural mesothelioma |
Pemshil 500mg Injection
Pemshil 500mg Injection is a prescription chemotherapy medicine containing pemetrexed, a multitargeted antifolate antineoplastic agent widely used in the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. This injectable anticancer drug interferes with essential enzymes involved in DNA and RNA synthesis, helping to inhibit cancer cell replication and slow tumor progression. Its targeted mechanism makes it an important component of modern lung cancer chemotherapy protocols.
Pemetrexed injection is commonly prescribed as monotherapy or in combination with other anticancer agents, depending on the stage and type of cancer. Pemshil 500 mg is administered through intravenous (IV) infusion in a clinical setting, ensuring accurate dosing and controlled delivery. The formulation is designed to provide consistent therapeutic efficacy while meeting strict pharmaceutical quality standards for oncology treatments.
Pemshil Injection must be used strictly under the guidance of a qualified oncologist, with appropriate premedication and monitoring to manage potential side effects. It is a prescription-only anticancer medicine, recommended for use in hospitals and specialized cancer care centers. Proper storage, handling, and administration are essential to maintain drug stability and patient safety, making Pemshil a trusted choice in advanced cancer therapy.
Product Features
- Multitargeted antifolate chemotherapy injection
- Contains Pemetrexed 500 mg
- Used in the treatment of NSCLC and pleural mesothelioma
- Commonly combined with cisplatin or carboplatin
- Administered via intravenous (IV) infusion
- Intended for hospital and clinical oncology use
- Manufactured under GMP-compliant standards
- Prescription-required anticancer medicine
How It Helps
- Inhibits key enzymes required for cancer cell DNA and RNA synthesis
- Slows tumor growth in non-small cell lung cancer and pleural mesothelioma
- Supports effective chemotherapy when used alone or with platinum agents
- Enables controlled treatment through supervised intravenous administration
Reviews
There are no reviews yet.